Switch theme
Sign up to access all valuation multiples
Balsm Alofoq Medical Co operates in the medical sector. Its activity includes medical services, clinics, specialized medical complexes, medical operation, and importing and supplying medical devices and .supplies to all regions of the Kingdom.
2012
n/a
Last FY Revenue $5.3M
Last FY EBITDA $1.7M
$16.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Balsm Alofoq achieved revenue of $5.3M and an EBITDA of $1.7M.
Balsm Alofoq expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Balsm Alofoq valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $5.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $2.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 47% | XXX | XXX | XXX |
| EBITDA | XXX | $1.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 32% | XXX | XXX | XXX |
| EBIT | XXX | $1.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 26% | XXX | XXX | XXX |
| Net Profit | XXX | $1.3M | XXX | XXX | XXX |
| Net Margin | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Balsm Alofoq's stock price is SAR 63 (or $17).
Balsm Alofoq has current market cap of SAR 79.2M (or $21.1M), and EV of SAR 62.7M (or $16.7M).
See Balsm Alofoq trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.7M | $21.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Balsm Alofoq has market cap of $21.1M and EV of $16.7M.
Balsm Alofoq's trades at 3.2x EV/Revenue multiple, and 9.9x EV/EBITDA.
Equity research analysts estimate Balsm Alofoq's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Balsm Alofoq's P/E ratio is not available.
See valuation multiples for Balsm Alofoq and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.1M | XXX | $21.1M | XXX | XXX | XXX |
| EV (current) | $16.7M | XXX | $16.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 12.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 16.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 11.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBalsm Alofoq's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Balsm Alofoq's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Balsm Alofoq's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Balsm Alofoq and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Balsm Alofoq acquired XXX companies to date.
Last acquisition by Balsm Alofoq was XXXXXXXX, XXXXX XXXXX XXXXXX . Balsm Alofoq acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Balsm Alofoq founded? | Balsm Alofoq was founded in 2012. |
| Where is Balsm Alofoq headquartered? | Balsm Alofoq is headquartered in Saudi Arabia. |
| Is Balsm Alofoq publicy listed? | Yes, Balsm Alofoq is a public company listed on SAU. |
| What is the stock symbol of Balsm Alofoq? | Balsm Alofoq trades under 9620 ticker. |
| When did Balsm Alofoq go public? | Balsm Alofoq went public in 2024. |
| Who are competitors of Balsm Alofoq? | Similar companies to Balsm Alofoq include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Balsm Alofoq? | Balsm Alofoq's current market cap is $21.1M |
| Is Balsm Alofoq profitable? | Yes, Balsm Alofoq is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
